Table 1.
Current clinical trials.
| Clinicial trial indentifier | Status | Phase | Cancer type | Epigenetic drug (target) | PD-1/PD-L1 |
|---|---|---|---|---|---|
| NCT02936752 | Recruiting | I | Treating patients with myelodysplastic syndrome after deoxyribonucleic acid (DNA) methyltransferase inhibitor (DNMTi) therapy failure | Entinostat (HDAC1, HDAC2, HDAC3) | Pembrolizumab |
| NCT03250962 | Recruiting | I/II | Hodgkin lymphoma | Decitabine (DNMT1, DNMT3A, DNMT3B) | SHR-1210 |
| NCT02961101 | Recruiting | I/II | Relapsed or refractory malignancies, including non-Hodgkin's lymphoma, hepatocellular carcinoma, breast cancer, ovarian cancer or lung cancer or renal-cell cancer | Decitabine (DNMT1, DNMT3A, DNMT3B) | Anti-PD-1 antibody |
| NCT03346642 | Recruiting | I/II | Primary mediastinal large B-cell lymphoma | Decitabine (DNMT1, DNMT3A, DNMT3B) | SHR-1210 |
| NCT02892318 | Suspended | I | Acute myeloid leukemia | Guadecitabine (DNMT1) | Atezolizumab |
| NCT03308396 | Recruiting | I/II | Advanced kidney cancer, clear cell renal cell carcinoma | Guadecitabine (DNMT1) | Durvalumab |
| NCT02508870 | Suspended | I | Myelodysplastic syndromes | Azacitidine (DNMT1) | Atezolizumab |
| NCT03161223 | Recruiting | I/II | Lymphoma | 5-Azacitidine (DNMT1) | Durvalumab |
| NCT01928576 | Recruiting | II | Non-small-cell lung cancer | Azacitidine (DNMT1), Entinostat (HDAC1, HDAC2, HDAC3) |
Nivolumab |
| NCT02890069 | Recruiting | I | Colorectal cancer, non-small-cell lung carcinoma, triple negative breast cancer, renal cell carcinoma | Panobinostat (HDAC) | PDR001 |
| NCT02619253 | Recruiting | I | Renal cell carcinoma, urinary bladder neoplasms | Vorinostat (HDAC1, HDAC2, HDAC3, HDAC7, HDAC11) | Pembrolizumab |
| NCT02512172 | Active, not recruiting | I | Colorectal cancer | Romidepsin/CC-486 (HDAC1, HDAC2) | Pembrolizumab |
| NCT02453620 | Recruiting | I | Breast adenocarcinoma, HER2/Neu negative invasive breast carcinoma | Entinostat (HDAC1, HDAC2, HDAC3) | Ipilimumab/Nivolumab |
| NCT02959437 | Active, not recruiting | I/II | Solid tumors advanced malignancies metastatic cancer | INCB057643 (BET), Azacitidine (DNMT1) |
Pembrolizumab |
| NCT03854474 | Recruiting | I/II | Advanced urothelial carcinoma, locally advanced urothelial carcinoma, metastatic bladder urothelial carcinoma | Tazemetostat (EZH2) | Pembrolizumab |
| NCT02220842 | Active, not recruiting | I | Lymphoma | Tazemetostat (EZH2) | Atezolizumab |
| NCT03337698 | Recruiting | I/II | Non-small-cell lung cancer | Tazemetostat (EZH2) | Atezolizumab |
| NCT03019003 | Recruiting | I/II | Head and neck cancer | Azacitidine (DNMT1) | Durvalumab |
| NCT03390296 | Recruiting | II | Acute myeloid leukemia | Azacitidine (DNMT1) | Avelumab |
| NCT02811497 | Recruiting | II | Microsatellite stable colorectal carcinoma, platinum resistant epithelial ovarian cancer type II, estrogen receptor positive and HER2 negative breast cancer | Azacitidine (DNMT1) | Durvalumab |
| NCT02935361 | Recruiting | I/II | Chronic myelomonocytic leukemia, myelodysplastic syndrome, recurrent acute myeloid leukemia with myelodysplasia-related changes | Guadecitabine (DNMT1) | Atezolizumab |
| NCT03179943 | Recruiting | II | Urothelial carcinoma | Guadecitabine (DNMT1) | Atezolizumab |
| NCT03206047 | Suspended | I/II | Platinum-resistant ovarian carcinoma, recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma | Guadecitabine (DNMT1) | Atezolizumab |
| NCT03590054 | Recruiting | I | Stage III cutaneous melanoma, stage IV cutaneous melanoma, locally advanced melanoma, locally advanced solid neoplasm | Abexinostat (pan-HDAC inhibitor) | Pembrolizumab |
| NCT03812796 | Recruiting | II | GI cancer | Domatinostat (HDAC1, HDAC2, HDAC3) | Avelumab |
| NCT03982134 | Not yet recruiting | I | Melanoma, non-small-cell lung cancer | Panobinostat (HDAC) | PDR001 |